Amgen Inc
USUSDAmgen Inc (MX:AMGN) — Biotechnology: Biological Products (No Diagnostic Substances). Numero di borse in cui sono quotate le azioni della società: 4. In questa pagina: prezzo e grafico, dividendi, principali azionisti e cronologia del numero di azioni.
Informazioni sull'Azienda
- Sito Web
- amgen.com
- Relazioni con gli Investitori
- investors.amgen.com/
- Settore
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Sede Centrale
- Thousand Oaks, United States
- Amministratore Delegato
- Robert A. Bradway
- Dipendenti
- 17 900
- Fondata
- 1980
- Quotata dal
- 29.02.2008 (MX:AMGN)
- Azioni in Circolazione
- 540.63 Mln al 2026-07-30
- Flottante
- 539.16 Mln
- Capitalizzazione di Mercato
- 226.05 Mld USD
- Insider
- 0.23%
- Investitori Istituzionali
- 85.02%
- Settore (SIC)
- Biological Products, (No Diagnostic Substances)
- Forma Giuridica
- XTIQ
- ISIN
- US0311621009
- LEI
- 62QBXGPJ34PQ72Z12S66
- Payout Ratio
- 60.4%
- FCF
- 10.2 Mld USD52%
- Debito
- 57.3 Mld USD4.3 anni di FCF
- Serie di Dividendi
- 15 a.
- Utili, FCF e dividendi pagati — per i 12 mesi fino a 30.06.2026 (l'ultimo rapporto dell'azienda).
Descrizione
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Borse e Ticker
| Borsa | Ticker | Valuta | Prezzo | Tipo |
|---|---|---|---|---|
| US USA Stocks | AMGN principale | USD | 407.44 -1.37% | azioni ordinarie |
| HK Hong Kong Stock Exchange | 4332 secondaria | HKD | — | |
| LSE London Stock Exchange | 0R0T IOB | USD | 411.854 +1.17% | azioni ordinarie |
| MX Mexican Stock Exchange | AMGN secondaria | MXN | 7 500.0098 +0.00% | azioni ordinarie |
| XETRA Xetra | AMG secondaria | EUR | 367.95 -1.39% | azioni ordinarie |
Dividendi
Amgen Inc (AMGN) paga dividendi trimestralmente. All'anno (12 mesi fino all'ultimo pagamento annunciato): 180.7291 MXN per azione (pagamenti: 4). Questo rappresenta circa il 2.41% del prezzo attuale delle azioni. In base alla storia dei pagamenti, la prossima data ex-dividendo è prevista intorno al 20.11.2026. Storia dei dividendi ininterrotta: 15 anni.
| Data Ex | Pagamento | Importo | % | Tipo | Ticker |
|---|---|---|---|---|---|
| 2026-08-21 | — | 45.8186 MXN | 0.6/2.4 % | trimestrale | MX:AMGN |
| 2026-05-15 | — | 45.8186 MXN | 0.6/2.4 % | trimestrale | MX:AMGN |
| 2026-02-13 | — | 45.8186 MXN | 0.6/2.3 % | trimestrale | MX:AMGN |
| 2025-11-21 | — | 43.2732 MXN | 0.6/2.3 % | trimestrale | MX:AMGN |
| 2025-08-22 | — | 43.2732 MXN | 0.6/2.3 % | trimestrale | MX:AMGN |
| 2025-05-16 | — | 43.2732 MXN | 0.6/2.2 % | trimestrale | MX:AMGN |
| 2025-02-14 | — | 43.2732 MXN | 0.6/2.2 % | trimestrale | MX:AMGN |
| 2024-11-19 | — | 40.9095 MXN | 0.5/2.2 % | trimestrale | MX:AMGN |
| 2024-08-16 | — | 40.9095 MXN | 0.5/2.2 % | trimestrale | MX:AMGN |
| 2024-05-16 | — | 40.9095 MXN | 0.5/2.1 % | trimestrale | MX:AMGN |
| 2024-02-15 | — | 40.9095 MXN | 0.5/2.1 % | trimestrale | MX:AMGN |
| 2023-11-16 | — | 38.7277 MXN | 0.5/2.1 % | trimestrale | MX:AMGN |
| 2023-08-17 | — | 38.7277 MXN | 0.5/2.0 % | trimestrale | MX:AMGN |
| 2023-05-17 | — | 38.7277 MXN | 0.5/2.0 % | trimestrale | MX:AMGN |
| 2023-02-14 | — | 38.7277 MXN | 0.5/1.9 % | trimestrale | MX:AMGN |
| 2022-11-16 | — | 35.2731 MXN | 0.5/1.9 % | trimestrale | MX:AMGN |
| 2022-08-17 | — | 35.2731 MXN | 0.5/1.8 % | trimestrale | MX:AMGN |
| 2022-05-16 | — | 35.2731 MXN | 0.5/1.4 % | trimestrale | MX:AMGN |
| 2022-02-14 | — | 35.2731 MXN | 0.5/0.9 % | trimestrale | MX:AMGN |
| 2021-11-16 | — | 32.0003 MXN | 0.4/0.4 % | trimestrale | MX:AMGN |
Principali Azionisti
| Detentore | Quota | Azioni | Data del Rapporto |
|---|---|---|---|
| Blackrock Inc. | 9.13% | 49.36 Mln | 2026-06-30 |
| Vanguard Capital Managem… | 6.52% | 35.25 Mln | 2026-06-30 |
| State Street Corporation | 5.65% | 30.56 Mln | 2026-06-30 |
| Capital World Investors | 5.38% | 29.08 Mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 17.13 Mln | 2026-06-30 |
| Invesco Ltd. | 3.02% | 16.32 Mln | 2026-06-30 |
| Geode Capital Management… | 2.9% | 15.7 Mln | 2026-06-30 |
| Charles Schwab Investmen… | 2.78% | 15.03 Mln | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.75% | 14.85 Mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 13.99 Mln | 2026-06-30 |
| Morgan Stanley | 2.53% | 13.65 Mln | 2026-06-30 |
| Invesco QQQ Trust, Serie… | 2.15% | 11.61 Mln | 2026-08-31 |
| SCHWAB STRATEGIC TRUST-S… | 1.81% | 9.79 Mln | 2026-05-31 |
| Income Fund of America | 1.44% | 7.76 Mln | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 7.28 Mln | 2026-07-31 |
| Wells Fargo & Company | 1.34% | 7.24 Mln | 2026-06-30 |
| AMERICAN BALANCED FUND | 1.31% | 7.09 Mln | 2026-06-30 |
| Fidelity Concord Street… | 1.29% | 6.98 Mln | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 6.6 Mln | 2026-08-31 |
| WASHINGTON MUTUAL INVEST… | 1.16% | 6.27 Mln | 2026-06-30 |
| BRADWAY ROBERT A (Chief… | ≈0.12% | 657 299 | 2026-05-05 |
| SANTOS ESTEBAN (Officer) | ≈0.02% | 84 279 | 2026-05-05 |
| GORDON MURDO (Officer) | ≈0.01% | 51 837 | 2026-05-05 |
| GRIFFITH PETER H. (Chief… | ≈0.01% | 50 706 | 2026-05-05 |
| REESE DAVID M. (Chief Te… | ≈0.01% | 42 812 | 2026-05-05 |
| GRAHAM JONATHAN P (Gener… | ≈0.01% | 40 211 | 2026-05-05 |
| BRADNER JAMES E. (Office… | ≈0.01% | 30 462 | 2026-05-05 |
| ECKERT ROBERT ANDREW (Di… | ≈0% | 26 251 | 2026-05-19 |
| JACKS TYLER (Director) | ≈0% | 18 284 | 2026-05-19 |
| KULLMAN ELLEN JAMISON (D… | ≈0% | 14 536 | 2026-05-19 |
